Based on the earlier reports of HHV-6 with both MS and PML [28], and the results in this study detecting HHV-6A DNA sequences in a subset of natalizumab treated MS patients (Figure 1), we investigated whether differential antibody responses between MS patients treated with and without natalizumab could be demonstrated. This evidence concerns the gene PML and myeloid sarcoma.